Nrx pharmaceuticals and quantum leap announce treatment of severely ill covid-19 patients with zyesamiÔ (aviptadil) in the i-spy covid trial

San francisco and radnor, pa., july 12, 2021 /prnewswire/ -- nrx pharmaceuticals, inc. ("nrx") (nasdaq: nrxp) and quantum leap healthcare collaborative™ (quantum leap) have begun treating patients with inhaled zyesamiÔ (aviptadil), in the i-spy covid trial (nct04488081), a phase 2 adaptive platform trial aimed at improving treatment for severely and critically ill covid-19 patients.
NRXP Ratings Summary
NRXP Quant Ranking